317 related articles for article (PubMed ID: 30479089)
21. Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.
Heeran MC; Høgdall CK; Kjaer SK; Christensen L; Jensen A; Blaakaer J; Christensen IJ; Høgdall EV
APMIS; 2013 Dec; 121(12):1177-86. PubMed ID: 23594232
[TBL] [Abstract][Full Text] [Related]
22. Pretreatment thrombocytosis as an independent predictive factor for chemoresistance and poor survival in epithelial ovarian cancer.
Nakao S; Minaguchi T; Itagaki H; Hosokawa Y; Shikama A; Tasaka N; Akiyama A; Ochi H; Matsumoto K; Satoh T
J Ovarian Res; 2020 May; 13(1):55. PubMed ID: 32375852
[TBL] [Abstract][Full Text] [Related]
23. Association Between Endometriosis and Prognosis of Ovarian Cancer: An Updated Meta-Analysis.
Chen P; Zhang CY
Front Oncol; 2022; 12():732322. PubMed ID: 35433452
[TBL] [Abstract][Full Text] [Related]
24. Thrombocytosis Portends Adverse Prognosis in Colorectal Cancer: A Meta-Analysis of 5,619 Patients in 16 Individual Studies.
Gu D; Szallasi A
Anticancer Res; 2017 Sep; 37(9):4717-4726. PubMed ID: 28870890
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis.
Xu K; Yang S; Zhao Y
Oncotarget; 2017 Jan; 8(1):285-302. PubMed ID: 27690218
[TBL] [Abstract][Full Text] [Related]
26. Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients.
Feng Z; Wen H; Bi R; Duan Y; Yang W; Wu X
BMC Cancer; 2016 Jan; 16():43. PubMed ID: 26817451
[TBL] [Abstract][Full Text] [Related]
27. BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis.
Kalachand RD; Stordal B; Madden S; Chandler B; Cunningham J; Goode EL; Ruscito I; Braicu EI; Sehouli J; Ignatov A; Yu H; Katsaros D; Mills GB; Lu KH; Carey MS; Timms KM; Kupryjanczyk J; Rzepecka IK; Podgorska A; McAlpine JN; Swisher EM; Bernards SS; O'Riain C; O'Toole S; O'Leary JJ; Bowtell DD; Thomas DM; Prieske K; Joosse SA; Woelber L; Chaudhry P; Häfner N; Runnebaum IB; Hennessy BT
J Natl Cancer Inst; 2020 Dec; 112(12):1190-1203. PubMed ID: 32413141
[TBL] [Abstract][Full Text] [Related]
28. Circulating tumor DNA as a biomarker for predicting progression-free survival and overall survival in patients with epithelial ovarian cancer: a systematic review and meta-analysis.
Taliento C; Morciano G; Nero C; Froyman W; Vizzielli G; Pavone M; Salvioli S; Tormen M; Fiorica F; Scutiero G; Scambia G; Giorgi C; Greco P; Pinton P
Int J Gynecol Cancer; 2024 Jun; 34(6):906-918. PubMed ID: 38658022
[TBL] [Abstract][Full Text] [Related]
29. The prognostic value of vascular endothelial growth factor in ovarian cancer: a systematic review and meta-analysis.
Yu L; Deng L; Li J; Zhang Y; Hu L
Gynecol Oncol; 2013 Feb; 128(2):391-6. PubMed ID: 23142075
[TBL] [Abstract][Full Text] [Related]
30. Prognostic and clinicopathological significance of C-reactive protein in patients with ovarian cancer: a meta-analysis.
Zhang W; Zhang Z; Qian L
World J Surg Oncol; 2024 Jan; 22(1):8. PubMed ID: 38172843
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of HER-2/neu expression in epithelial ovarian cancer: a systematic review and meta-analysis.
Wang K; Guan C; Yu J; Jin X; Sun L; Zheng L; Xia L; Zhang Y
Oncotarget; 2017 Sep; 8(43):75528-75543. PubMed ID: 29088888
[TBL] [Abstract][Full Text] [Related]
32. The association of pretreatment thrombocytosis with prognosis and clinicopathological significance in cervical cancer: a systematic review and meta-analysis.
Cheng J; Zeng Z; Ye Q; Zhang Y; Yan R; Liang C; Wang J; Li M; Yi M
Oncotarget; 2017 Apr; 8(15):24327-24336. PubMed ID: 28212582
[TBL] [Abstract][Full Text] [Related]
33. Enrichment and detection method for the prognostic value of circulating tumor cells in ovarian cancer: A meta-analysis.
Huang C; Lin X; He J; Liu N
Gynecol Oncol; 2021 May; 161(2):613-620. PubMed ID: 33674144
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Significance of the Metabolic Marker Hexokinase-2 in Various Solid Tumors: A Meta-Analysis.
Liu Y; Wu K; Shi L; Xiang F; Tao K; Wang G
PLoS One; 2016; 11(11):e0166230. PubMed ID: 27824926
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Value of Elevated Pre-treatment Serum CA-125 in Epithelial Ovarian Cancer: A Meta-Analysis.
Wang Q; Feng X; Liu X; Zhu S
Front Oncol; 2022; 12():868061. PubMed ID: 35463345
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological and prognostic significance of thyroid transcription factor-1 expression in small cell lung cancer: A systemic review and meta-analysis.
Wang Y; Wu Y; Li J; Li J; Che G
Pathol Res Pract; 2019 Dec; 215(12):152706. PubMed ID: 31704153
[TBL] [Abstract][Full Text] [Related]
37. The role systematic lymphadenectomy plays in determining the survival outcome for advanced ovarian cancer patients: a meta-analysis.
Xu D; Xue J; Rozan R; Li L
Ann Palliat Med; 2020 May; 9(3):912-920. PubMed ID: 32389005
[TBL] [Abstract][Full Text] [Related]
38. Pretreatment thrombocytosis predict poor prognosis in patients with endometrial carcinoma: a systematic review and meta-analysis.
Nie D; Yang E; Li Z
BMC Cancer; 2019 Jan; 19(1):73. PubMed ID: 30646853
[TBL] [Abstract][Full Text] [Related]
39. Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials.
Wu YS; Shui L; Shen D; Chen X
Oncotarget; 2017 Feb; 8(6):10703-10713. PubMed ID: 27793044
[TBL] [Abstract][Full Text] [Related]
40. The survival detriment of venous thromboembolism with epithelial ovarian cancer.
Gunderson CC; Thomas ED; Slaughter KN; Farrell R; Ding K; Farris RE; Lauer JK; Perry LJ; McMeekin DS; Moore KN
Gynecol Oncol; 2014 Jul; 134(1):73-7. PubMed ID: 24793732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
